ClinicalTrials.gg
Not yet recruitingNCT07371429Updated Sep 28, 2026

A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics

A Phase 1 interventional study of Gepotidacin and SOC in Urinary Tract Infections, sponsored by GlaxoSmithKline. Not yet recruiting at 4 sites in United States. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Updated Sep 28, 2026First site in United StatesStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Planned enrollment
9th of 13
25 · median 61
Started
2026
with 2 others
Phase 1
5 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 12th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment with antibacterials for a confirmed or suspected infection or for its prevention.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • Gepotidacin
  • Antibacterial Standard of Care
  • Antibiotics
  • Bacterial Infection
  • Urinary Tract Infections
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants having ≥2 to \<12 years of age at the time of signing the /assent and have a body weight >=10 kilograms (kg).
  • Participants receiving SoC antibacterial therapy for a confirmed/suspected infection or for prophylaxis AND is able to take a single dose of the powder for oral suspension formulation of gepotidacin after a meal.
  • Participants either hospitalized or in an overnight clinic. Participant is expected to be in hospital/clinic for at least 24 hours post administration of study intervention.

Participant has an indwelling venous catheter in place as part of the clinical SoC.

  • Male or female according to their reproductive organs at birth.
  • Pregnancy testing is required as appropriate for the age, sexual activity, and sexual maturity of pediatric participants and as required by local regulations. Investigator should apply clinical judgment.
  • A female participant is eligible to participate if she is a who is not pregnant as confirmed by a high sensitivity serum or urine pregnancy test at baseline (Day 1) regardless of current or prior use or abstinence, is not breastfeeding, or is not a WOCBP.
  • Participant LAR(s) who has the ability to understand, agree to, and sign the informed consent form before initiation of any protocol-related procedures; participant has the ability to give documented assent.
  • Participant and participant's LAR are willing and able to comply with study instructions, study visits, and procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants having a -for-age that is less than the 5th percentile or greater than the 95th percentile based on the CDC percentiles [CDC NCHS Growth Charts].
  • Participants having a medical history, including , significant chromosome abnormality, neurological disorder or history of seizure (excluding simple febrile seizure), chronic disease, active tuberculosis or acute hepatitis.
  • Participants with serious disease/condition that could be imminently life-threatening (e.g. is clinically/hemodynamically unstable, is septicemic, has severe sepsis, organ failure, requiring ITU care or has clinical laboratory tests either nonstable or anticipated to be nonstable) or the participant is unlikely to survive for the duration of the study period.
  • The participant has severe renal organ dysfunction or has known anuria, oliguria, or significant impairment of renal function ( \<60 mL/min or clinically significant elevated serum creatinine as determined by the investigator).
  • The participant has a significant CV history or based on investigator judgment any clinically significant abnormal reading at Screening/baseline (e.g., prolonged syndrome).
  • The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of complications (e.g., uncontrolled diabetes in the judgment of the investigator, transplant recipients (with the exception of cornea and BMT), participants with clinically significant persistent granulocytopenia [ \<1000/μL], and participants receiving immunosuppressive therapy, including therapy at a dose of >1 mg/kg/day of prednisolone or equivalent for >1 week or 0.5-\<1 mg/kg/day prednisolone or equivalent for >2 weeks). Participants aged ≥6 years with a known of \<200 cells/mm3 and participants aged \<6 years with a known CD4 count of \<500 cells/mm3 are to not be enrolled.
  • The participant has any of the following medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as:

    • Poorly controlled asthma or obstructive pulmonary disease at baseline and, in the opinion of the investigator, not stable on current therapy.
    • Active peptic ulcer disease
    • Juvenile Parkinson disease
    • Juvenile Myasthenia gravis
  • The participant has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention (e.g., ileostomy or malabsorption syndrome).
  • The participant plans to use any of the prohibited medications or nondrug therapies from the Baseline Visit through Follow-up Visit at 7 ±3 days after the single dose of study intervention.
  • The participant has received a prohibited medication within 14 days or 5 half-lives prior to gepotidacin administration, whichever is longer.
  • The participant has been previously enrolled in this study or has previously been treated with gepotidacin.
  • The participant has participated in a clinical trial and has received an product within 30 days or 5 half-lives prior to gepotidacin administration, whichever is longer.
  • The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.
  • If the child is being breastfed:

    • There is suspicion of current alcohol or substance misuse/abuse in breastfeeding mother.
    • The breastfeeding mother is taking any medication or any substances containing any of the medications included in the prohibited medication list with known or unknown lactation excretion.
  • The participant has severe hepatic organ dysfunction.
  • The participant has an value >2 × .
  • The participant has a total >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is ≤1.5xULN.
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • The participant has congenital long QT syndrome or known prolongation of the QTc interval.
  • The participant has uncompensated heart failure.
  • The participant has severe left ventricular hypertrophy.
  • The participant has a family history of QT prolongation or sudden death or history of sudden infant death in a sibling.
  • The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.
  • The participant is taking QT-prolonging drugs or drugs known to increase the risk of TdP per the ww.crediblemeds.org. "Known Risk of TdP" category at the time of the Baseline Visit, which cannot be safely discontinued from the Baseline Visit (Day 1) through 7 (+3) days after the single dose of study intervention; or the participant is taking a strong inhibitor.
  • The participant has a mean triplicate QTc >450 msec or a mean triplicate QTc >480 msec for participants with complete bundle branch block.
  • The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Gepotidacin plus Standard of care (SOC)

    Single Arm

    Drug: Gepotidacin · Drug: SOC

Interventions

  • Gepotidacin will be administered

  • DrugSOC

    SOC will be administered

06

What researchers measure

Primary outcomes

  1. AUC from time zero to the time of the last quantifiable concentration (AUC[0-t]) of gepotidacin

    Time frame: Up to 24 hours post dose (Day 1)

  2. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC[0-inf]) of gepotidacin

    Time frame: Up to 24 hours post dose (Day 1)

  3. Maximum observed plasma concentration (Cmax) of gepotidacin

    Time frame: Up to 24 hours post dose (Day 1)

  4. Apparent oral clearance (CL/F) of gepotidacin

    Time frame: Up to 24 hours post dose (Day 1)

  5. Apparent volume of distribution (Vz/F) of gepotidacin

    Time frame: Up to 24 hours post dose (Day 1)

  6. Terminal phase half-life (t1/2) of gepotidacin

    Time frame: Up to 24 hours post dose (Day 1)

Secondary outcomes

  1. Number of participants with Adverse events (AEs), Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs)

    Time frame: Up to 7 days (±3 days)

  2. Change from baseline in vital signs: Temperature

    Time frame: At 2 hours (±15 mins) post dose on Day 1

  3. Change from baseline in vital signs: Blood Pressure

    Time frame: At 2 hours (±15 mins) post dose on Day 1

  4. Change from baseline in vital signs: Pulse Rate

    Time frame: At 2 hours (±15 mins) post dose on Day 1

  5. Change from baseline in Electrocardiogram (ECG)

    Time frame: At 2 hours (±15 mins) post dose on Day 1

07

Study locations

4 sites
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71101, United States
  • GSK Investigational Site
    Baltimore, Maryland 21827, United States
  • GSK Investigational Site
    St Louis, Missouri 63110-1010, United States
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 11 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 28, 2026
StartEst.
Sep 18, 2026was Apr 2026
Primary completionEst.
Aug 23, 2027
CompletionEst.
Aug 23, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • GSK Investigational Site · Orange, United States
  • GSK Investigational Site · Shreveport, United States
  • GSK Investigational Site · Baltimore, United States
  • GSK Investigational Site · St Louis, United States
Sep 28, 2026
Start date
Apr 29, 2026→Sep 18, 2026
Sep 28, 2026
Enrollment
20→25
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • GSK Investigational Site · Orange, United States
    • GSK Investigational Site · Shreveport, United States
    • GSK Investigational Site · Baltimore, United States
    • GSK Investigational Site · St Louis, United States
    Start date Apr 29, 2026→Sep 18, 2026
    Enrollment 20→25
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07371429
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Sep 18, 2026 (estimated)
Primary completion
Aug 23, 2027 (estimated)
Completion
Aug 23, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion